- Services
- Team
- Patient Education
- Diagnosing MS
- Understanding Some Basics About MS
- Relapsing Remitting MS
- Secondary Progressive MS
- Primary Progressive MS
- Preparing for Your New Patient Visit
- Preparing for a Spinal Tap
- Injection & Medication Counseling
- Relapse vs. Pseudorelapse
- Neuromyelitis Optics vs. Multiple Sclerosis
- Resources
- FAQ
- Research
- News
- Contact
- Leave a Review
BG-12 Phase III Results presented at ECTRIMS
Phase III results for another emerging oral medication for MS were presented at ECTRIMS this weekend. The DEFINE trial evaluated the use of dimethyl fumarate (also known as BG-12) versus placebo in patients with MS. The study met the primary endpoint of a reduction in relapse rate as well as multiple MRI endpoints. The safety profile of this medication seems to be very good. Below is a link to an article with a nice summary of the results.
News Date :
Monday, October 24, 2011 - 18:42
IMSMP
Because you deserve only the best in MS healthcare. Experience the difference.
News & Events
Newsletter Sign Up
Join our mailing list today! Receive the latest information and updates happening in MS research, treatment and care including, Healing MS, the IMSMP newsletter.
* We don’t share your information with anyone.